Navigation Links
Aeras-led research consortium receives FDA support

Rockville, MD, USA (October 4, 2010) The Aeras Global TB Vaccine Foundation is pleased to announce receipt of a grant from the United States Food and Drug Administration (FDA) to develop new biological and immunological biomarkers for TB vaccine development. The FDA grant, which supports the coordination of a multi-investigator project with researchers from the United States, the United Kingdom and South Africa, will provide $362,102 in the first year of funding. The project is anticipated to cost $785,940 over three years.

"We are grateful for this show of support from the Food and Drug Administration for TB vaccine research," said Thomas G. Evans, MD, Chief Scientific Officer of the Aeras Global TB Vaccine Foundation. "Functional and biologically relevant immunological responses that correlate with vaccine efficacy remain elusive for tuberculosis so we are fortunate to be working with leaders in bioassay research to tackle this essential component of TB vaccine development."

The global TB epidemic continues to grow more complex and difficult to treat. The currently available TB vaccine called Bacille Calmette-Gurin has limited efficacy in preventing all forms of TB. BCG was developed before modern biotechnological advances and its method of eliciting immune response is not fully understood by researchers. Currently, there are 10 investigational TB vaccines designed as boosters or potential replacements for the BCG vaccine currently undergoing or poised to enter clinical testing and many more in the product development pipeline.

To effectively assess these and future investigational TB vaccines, biomarkers correlated with vaccine effectiveness are needed. A biomarker would facilitate clinical studies of vaccines across research institutions, geographic locations and within different target age groups and populations, standardizing and streamlining the regulatory review of clinical trial data.

"The development of biomarkers, particularly those that measure bacteriocidal effects correlated with TB vaccine effectiveness, could help shorten timeframes for introducing new TB vaccines, as we work with regulatory agencies like the FDA to conduct clinical trials and approve new TB vaccines," said Michael Brennan, PhD, Senior Advisor for Global Affairs at Aeras.

The project aims to evaluate four mycobacterial growth inhibition assays that can be reproducibly transferred to other laboratories and to identify T-cell immune and antibody responses that may be associated with ex vivo growth inhibition and potentially with protective vaccines.

The consortium is comprised of researchers at the Aeras Global TB Vaccine Foundation; the Jenner Institute, University of Oxford; the South African Tuberculosis Vaccine Initiative of the University of Cape Town; Saint Louis University; and Albert Einstein College of Medicine.


Contact: Annmarie Leadman
Aeras Global TB Vaccine Foundation

Related biology news :

1. McGill partners with leading Swiss neuroscience research group
2. Bonn researchers use light to make the heart stumble
3. Hebrew University research holds promise for development of new osteoporosis drug
4. Earlier, more accurate prediction of embryo survival enabled by Stanford research
5. Researchers engineer adult stem cells that do not age
6. Research becomes a reality for Rett syndrome through new funding
7. OU researchers selected by Navy
8. RIT receives federal grant to construct new sustainability research facility
9. Iowa State University researcher examines mosquito gene for new disease response
10. NIH awards Rutgers $47.5 million to advance groundbreaking research on protein structures
11. NIH Transformative Research Project Awards hasten innovation
Post Your Comments:
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
Breaking Biology Technology: